Cogent Biosciences (COGT) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Incyte (INCY) over the past year, gaining 91.5% versus a gain of 33.1%. Over five years, COGT leads with a +235.5% price change compared with +72.0% for INCY. Incyte is the larger company by market cap ($22.86 billion vs $5.38 billion), about 4.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | INCY |
|---|---|---|
| Share price | $31.00 | $112.79 |
| Market cap | $5.38B | $22.86B |
| 1-day change | +3.06% | +0.04% |
| YTD return | -12.73% | +14.19% |
| 1-year return | +91.48% | +33.09% |
| 5-year return | +235.50% | +72.04% |
| P/E ratio (TTM) | — | 14.35 |
| Forward P/E | — | 12.89 |
| EPS (TTM) | $-2.16 | $7.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.14B |
| Revenue growth (YoY) | — | +21.22% |
| Net income (latest FY) | $-328.94M | $1.29B |
| Gross margin | — | 92.76% |
| Operating margin | — | 29.46% |
| Net margin | — | 25.03% |
| 52-week high | $43.73 | $132.60 |
| 52-week low | $13.78 | $82.82 |
| Distance from 52-week high | -29.11% | -14.94% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +80.06% | +14.49% |
| Average volume | 1.90M | 1.63M |
| Shares outstanding | 173.52M | 202.70M |
| Employees | 258 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 4.3 times larger than Cogent Biosciences by market value ($22.86B vs $5.38B).
- COGT has outperformed INCY by 58.4 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
COGT vs INCY FAQ
Which is bigger, Cogent Biosciences or Incyte?
Incyte (INCY) is larger, with a market capitalization of $22.86B compared with $5.38B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or INCY?
COGT returned +91.48% over the past 12 months, compared with +33.09% for INCY (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Incyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cogent Biosciences and Biotechnology: Commercial Physical & Biological Resarch for Incyte.